Screener
ADMA Biologics ADMA EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from ADMA Biologics’s reported figures.
Based on trailing twelve months.
The source filing: ADMA Biologics’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 5:16 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001140361-26-031445
FAQ
- What is ADMA Biologics's EBITDA margin?
- ADMA Biologics (ADMA) reported EBITDA margin of 45.3% in Q2 2026.
- How has ADMA Biologics's EBITDA margin changed year-over-year?
- ADMA Biologics's EBITDA margin increased by 31.4% year-over-year, from 34.5% to 45.3%.
- What is the long-term trend for ADMA Biologics's EBITDA margin?
- Over 5 years (2020 to 2025), ADMA Biologics's EBITDA margin has grown at a -23.0% compound annual growth rate (CAGR), from -144.4% to 39.1%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.
Ask your AI about ADMA Biologics's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude